(NewsNation) — The U.S. Food and Drug Administration plans to unveil a quicker approach to approving custom gene-editing treatments.

According to Bloomberg News, Vinay Prasad, who oversees gene therapies at the FDA, said the plans will be published in early November. He foresees the approach sparking curiosity for the next wave of doctors to develop treatments for conditions that only concern a small number of people.

“Regulation has to evolve as fast as science evolves,” Prasad said. "The agency is going to be extremely flexible and work very fast with the scientists who want to bring these therapies to kids who need it.”

“The moment we publish our paper, the investment in this space will flow. It will turn the spigot on.”

As a result of the news, the shares of CRISPR Therapeutics, Ed

See Full Page